文献速递胸部肿瘤

曲妥珠单抗瑞泽替康(HER2靶向抗体偶联药物)治疗晚期HER2突变非小细胞肺癌(HORIZON-Lung):多中心单臂2期研究结果

Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study.
PubMed 文献 · Lancet Oncol · 2025-02-25

这项在中国35家医院开展的多中心单臂2期研究,评估曲妥珠单抗瑞泽替康4.8 mg/kg每3周静脉给药治疗经治HER2突变晚期非小细胞肺癌的疗效与安全性。94例患者确认客观缓解率为73%(95% CI 63.3-82.0),常见3-4级治疗相关不良事件为中性粒细胞计数降低(40%)等,无治疗相关死亡。

要点

  • 曲妥珠单抗瑞泽替康4.8 mg/kg每3周一次,在经治HER2突变晚期NSCLC中确认客观缓解率达73%。
  • 常见3-4级治疗相关不良事件包括中性粒细胞计数降低40%、白细胞计数降低27%、贫血23%。
  • 治疗相关严重不良事件发生率为23%,包括血小板计数降低6%、中性粒细胞计数降低6%、间质性肺病5%。

核心结论

  • 曲妥珠单抗瑞泽替康在经治HER2突变非小细胞肺癌中显示出有临床意义的抗肿瘤活性和可控的安全性。
  • 作者认为值得开展进一步试验。

研究设计与样本

  • 多中心、单臂2期试验,在中国35家医院开展,纳入年龄18-75岁、局部晚期或转移性NSCLC伴活化HER2突变、ECOG体能状态评分0-1、铂类化疗及抗PD-1或抗PD-L1治疗后进展或不耐受的患者。
  • 曲妥珠单抗瑞泽替康4.8 mg/kg静脉给药,每3周一次。
  • 主要终点为独立评审委员会评估的客观缓解率,分析人群为至少接受一个周期研究治疗的患者;安全性分析纳入所有至少接受一个周期研究治疗的患者。
  • 2023年4月14日至2023年12月14日共入组并治疗94例患者;42例(45%)男性,52例(55%)女性,92例(98%)汉族,2例(2%)其他民族中国人。
  • 数据截止2024年6月14日,中位随访时间8.7个月(IQR 7.0-10.4)。

主要发现

  • 94例患者中69例(73%;95% CI 63.3-82.0)经独立评审委员会确认客观缓解。
  • 最常见的3-4级治疗相关不良事件为中性粒细胞计数降低(38例[40%])、白细胞计数降低(25例[27%])、贫血(22例[23%])、血小板计数降低(10例[11%])、淋巴细胞计数降低(7例[7%])。
  • 治疗相关严重不良事件发生于22例(23%)患者,包括血小板计数降低(6例[6%])、中性粒细胞计数降低(6例[6%])、间质性肺病(5例[5%])、白细胞计数降低(4例[4%])、贫血(4例[4%])、呕吐(3例[3%])、肺炎(3例[3%])、低钠血症(2例[2%])、发热(1例[1%])、小肠梗阻(1例[1%])、恶心(1例[1%])、慢性阻塞性肺疾病(1例[1%])。
  • 无治疗相关死亡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trastuzumab rezetecan (also known as SHR-A1811) is a novel antibody-drug conjugate consisting of a humanised HER2-directed monoclonal antibody, cleavable tetrapeptide-based linker, and DNA topoisomerase I inhibitor. In the phase 1 portion of this phase 1/2 study, trastuzumab rezetecan showed preliminary anti-tumour activity and a favourable safety profile in patients with HER2-mutant non-small-cell lung cancer (NSCLC). We present phase 2 results from the study, which aimed to further evaluate the activity and safety of trastuzumab rezetecan at the recommended dose. METHODS: In this multicentre, single-arm, phase 2 trial, conducted in 35 hospitals in China, we recruited patients aged 18-75 years, with locally advanced or metastatic NSCLC with an activating HER2 mutation and an Eastern Cooperative Oncology Group performance status score of 0-1, who had disease progression after or were intolerant to platinum-based chemotherapy and anti-PD-1 treatment or anti-PD-L1 treatment. Trastuzumab rezetecan was administered at 4·8 mg/kg intravenously once every 3 weeks. The primary endpoint was objective response rate assessed by an independent review committee in patients who received at least one cycle of study treatment. All patients who received at least one cycle of study treatment were included in safety analyses. This study is registered with ClinicalTrials.gov, NCT04818333, and is ongoing but not recruiting. FINDINGS: Between April 14, 2023, and Dec 14, 2023, 94 patients were enrolled and treated. 42 (45%) patients were male, 52 (55%) female, 92 (98%) were Han Chinese, and two (2%) were other ethnicity Chinese. At data cutoff (June 14, 2024), the median duration of follow-up was 8·7 months (IQR 7·0-10·4). 69 (73%; 95% CI 63·3-82·0) of 94 patients had a confirmed objective response, as assessed by independent review committee. The most common grade 3-4 treatment-related adverse events were decreased neutrophil count (38 [40%] patients), decreased white blood cell count (25 [27%]), anaemia (22 [23%]), decreased platelet count (10 [11%]), and decreased lymphocyte count (seven [7%]). Treatment-related serious adverse events occurred in 22 (23%) patients, which were decreased platelet count (six [6%]), decreased neutrophil count (six [6%]), interstitial lung disease (five [5%]), decreased white blood cell count (four [4%]), anaemia (four [4%]), vomiting (three [3%]), pneumonia (three [3%]), hyponatraemia (two [2%]), and pyrexia (one [1%]), small intestinal obstruction (one [1%]), nausea (one [1%]), and chronic obstructive pulmonary disease (one [1%]). There were no treatment-related deaths. INTERPRETATION: Trastuzumab rezetecan showed clinically meaningful activity and manageable safety in patients with previously treated HER2-mutant NSCLC. Further trials are justified. FUNDING: Jiangsu Hengrui Pharmaceuticals, National Multi-disciplinary Treatment Project for Major Diseases, Collaborative Innovation Center for Clinical and Translational Science by the Ministry of Education & Shanghai. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Li Z, Wang Y, Sun Y, et al. Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study. Lancet Oncol. 2025. PMID: 40020696. doi:10.1016/S1470-2045(25)00012-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。